OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human...

Area of Science:

• Hepatobiliary Medicine
• Cancer Biology
• Molecular Oncology

Background:

• Olfactomedin 4 (OLFM4) is implicated in hepatocellular carcinoma (HCC) pathogenesis.
• The precise mechanisms by which OLFM4 influences the GRIM19-STAT3 signaling axis in HCC are not fully understood.
• Cancer stem cell-like properties are crucial in HCC progression and recurrence.

Purpose of the Study:

• To elucidate the regulatory role of OLFM4 in the GRIM19-STAT3 pathway within HCC.
• To investigate the association between OLFM4, cancer stem cell markers (LGR5, CD133), and HCC patient prognosis.
• To evaluate OLFM4 as a potential prognostic biomarker and therapeutic target for HCC.

Main Methods:

• Analysis of OLFM4, GRIM19, and STAT3 expression in 111 HCC surgical specimens and HCC cell lines.
• In vitro experiments involving OLFM4 and GRIM19 knockdown to assess STAT3 activation and cellular behavior.
• Investigation of the LGR5-Wnt signaling pathway's role in OLFM4-mediated cancer stem cell properties.

Main Results:

• OLFM4 expression was significantly elevated in HCC tissues and correlated with poor prognosis.
• OLFM4 negatively regulated GRIM19 and positively modulated STAT3 activation, promoting cell cycle progression.
• OLFM4 knockdown reduced tumor cell proliferation, induced apoptosis, suppressed stem cell-like properties, and decreased recurrence incidence.
• LGR5 expression positively correlated with OLFM4 and CD133 expression, indicating poor prognosis.

Conclusions:

• OLFM4, induced by the LGR5-Wnt pathway, drives aggressive HCC progression and poor prognosis by enhancing STAT3-mediated proliferation and stem cell-like traits.
• OLFM4 serves as a novel prognostic predictor for HCC.
• OLFM4 represents a potential therapeutic target for HCC treatment.